

REIG JOFRE WILL LEAD THE MARKETING DEVELOPMENT IN EUROPE OF A NUTRITIONAL SUPPLEMENT AGAINST TUBERCULOSIS, DEVELOPED BY THE BIOTECHNOLOGICAL COMPANY MANREMYC

- Nyaditum resae® is a nutritional supplement developed by the biotechnological company Manremyc, a spin-off of the Institute Germans Trias i Pujol led by Dr. Pere-Joan Cardona.
- The agreement is part of Reig Jofre's commitment to the development of the biotech industry and the collaborative model of "open innovation" in a strategic sector for the company.
- Nyaditum resae® will be on the market for the first time in 2016, in India -the country with the highest incidence of tuberculosis in the world-, through an agreement between Manremyc and Tablets India. In Europe, the estimation is that the product shall be available in late 2017.

Barcelona, September 17, 2015. Spanish pharmaceutical company Reig Jofre and Manremyc, the biotechnological spin-off created from the Germans Trias i Pujol Health Sciences Research Institute (IGTP), have signed a collaboration agreement for the marketing development in Europe of Nyaditum resae®, an innovative nutritional supplement against tuberculosis (TB).

This nutritional supplement, the result of more than fifteen years of research led by Dr. Pere-Joan Cardona at IGTP, targets to reduce the risk of developing the disease in both people who carry the tuberculosis bacteria and those at risk of infection.

Since 1997 Dr. Pere-Joan Cardona's research team works in the eradication of tuberculosis, a field in which Dr. Cardona is the author of 16 patents (including the active ingredient in Nyaditum resae®) and of one hundred scientific papers.



According to the World Health Organization (WHO), tuberculosis is the second cause of death worldwide, due to a single infectious agent, responsible for 1.5 million deaths annually and 100 million new infections, of which 9 million develop the disease. In Europe, although the incidence is lower, 1.5 million people are carriers of the bacteria with an annual progression of 70 thousand new cases and 2,000 deaths.

Latent tuberculosis infection is very common. That means that despite the presence of tuberculosis bacteria (*Mycobacterium tuberculosis*) in the body, infected people may not develop the disease or take many years to develop it. This nutritional supplement targets the immune system to tolerate the tuberculosis bacillus, normally lodged in the lungs, and therefore, avoid an immune response that triggers the disease.

WHO recommend in people who carry the tuberculosis bacteria, a six-month treatment with antibiotics to prevent the development of the disease. Clinical trials have concluded that Nyaditum resae®, which is administered in tablets for two weeks, generates a protective immune response that reduces the incidence of tuberculosis disease.

The regulatory effect provided by this innovative nutraceutical is recommended not only in people who carry the bacteria or are at risk of infection, but also in those who have already suffered the disease, due to their genetic predisposition to re-develop it, as well as in those population segments most exposed to it, such as type 2 diabetics.

Under the agreement signed with Manremyc, Reig Jofre will lead the development and marketing phases in Europe, including the incorporation of Nyaditum resae® as novel food in the European Food Safety Agency (EFSA) records, as well as its production at Reig Jofre's facilities. The product is estimated to be on the market in Europe in late 2017.

This project is of double interest to Reig Jofre. On one side, it is part of the strategic focus of the company for disease prevention and not just healing, a strategy recently reinforced by the incorporation of the nutritional supplements pharmaceutical company Forte Pharma. On the other hand, through the agreement with Manremyc, Reig Jofre consolidates its commitment to "open innovation", a collaboration model with start-ups and biotechnological research centers, to support complex process of technology transfer to the market.



According to Ignasi Biosca, CEO of Reig Jofre and president of CataloniaBio, the Catalan Association of Biotechnological Companies: *"It is essential that from the consolidated pharmaceutical companies, we support research centers and biotechnological start-ups for the complex and costly process that involves technology transfer to society and that we contribute to the important mission of developing solutions not only for the control of diseases but also for its prevention, as here tuberculosis."*

Receive promptly Reig Jofre's news by registering in the company's **subscription center** of the new corporate website: **www.reigjofre.com**

About Reig Jofre

After the merger between Laboratorio Reig Jofre and Natraceutical, the new Reig Jofre is a pharmaceutical company whose business is divided into two major areas: one main for the development, manufacture and marketing of own products (approximately 78% of sales) and one of specialized manufacturing for thirds (22% of sales). At its core activity, the company specializes in the development of prescription and non-prescription pharmaceutical products, injectable generics based on specialized technologies, medical devices, food supplements and cosmetics. The company directs its R&D to develop new indications and/or dosage forms of known active principles, generic medicines with a special focus on beta lactam and lyophilized injectable antibiotics, topical dermatological products, OTCs and food supplements as well as the development of new innovative molecules in partnership with start-ups and research centers.

Reig Jofre trades on the Spanish stock exchange under the ticker RJF. Total outstanding shares: 1,264,284,408

For further information

Media

Ricardo Franco
ATREVIA
Tel. +34 93 419 06 30
rfranco@atrevia.es

Investors and analysts

Gloria Folch
Head of Investor Relations
REIG JOFRE
Tel. +34 93 584 81 85
gloria.folch@reigjofre.com